CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Cullinan Therapeutics (CGEM) shares tumbled as much as 12% on Thursday after the company outlined fourth-quarter pipeline updates that pushed rheumatoid arthritis data later than previously signaled.The decline reflected a broader sell-off in clinical-stage biotech names and investor disappointment…